Kaplowitz L G, Vishniavsky N, Evans T, Vartivarian S, Dalton H, Simpson M, Gruninger R P
Am J Med. 1987 Jun 26;82(6B):35-9. doi: 10.1016/0002-9343(87)90616-4.
Norfloxacin, an oral fluoroquinolone antibacterial, is active in vitro against a variety of gram-positive and gram-negative pathogens, including both penicillinase-producing and non-penicillinase-producing strains of Neisseria gonorrhoeae. An earlier study demonstrated that a two-dose regimen of norfloxacin was as effective as standard therapy with spectinomycin for treating gonococcal urethritis, including infections caused by penicillinase-producing organisms. In this randomized study of treatment for uncomplicated gonococcal infection in men and women, three oral treatment regimens were compared: patients received either two doses of norfloxacin (600 mg twice daily), a single dose of norfloxacin (800 mg), or a single-dose ampicillin (3.5 g)/probenecid (1.0 g) regimen (as recommended by the Centers for Disease Control). All three treatment regimens achieved similar cure rates. Although the number of patients treated was too small to yield statistically significant conclusions, it appears that norfloxacin may be slightly better treatment for rectal and pharyngeal gonococcal infections than ampicillin and probenecid. Additionally, norfloxacin was well tolerated in this study. Thus, based on a review of these data, norfloxacin appears to be an alternative, single-dose, oral treatment regimen for uncomplicated gonococcal infection.
诺氟沙星是一种口服氟喹诺酮类抗菌药，在体外对多种革兰氏阳性和革兰氏阴性病原体具有活性，包括产青霉素酶和不产青霉素酶的淋病奈瑟菌菌株。一项较早的研究表明，诺氟沙星两剂疗法治疗淋菌性尿道炎，包括由产青霉素酶的生物体引起的感染，与标准的大观霉素疗法一样有效。在这项针对男性和女性单纯性淋菌感染治疗的随机研究中，比较了三种口服治疗方案：患者分别接受两剂诺氟沙星（每日两次，每次600毫克）、一剂诺氟沙星（800毫克）或一剂氨苄西林（3.5克）/丙磺舒（1.0克）方案（按照疾病控制中心的建议）。所有三种治疗方案的治愈率相似。尽管接受治疗的患者数量太少，无法得出具有统计学意义的结论，但似乎诺氟沙星治疗直肠和咽部淋菌感染可能比氨苄西林和丙磺舒稍好。此外，在本研究中诺氟沙星耐受性良好。因此，基于对这些数据的审查，诺氟沙星似乎是一种用于单纯性淋菌感染的替代单剂量口服治疗方案。
